Shigefumi Yoshino

Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer

Taichi Kuwahara, Shoichi Hazama, Nobuaki Suzuki et al. · British Journal of Cancer · 2019 · 126 citations · Full text

Medicine, Oncology, Pathology +17

Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.

Hiroshi Kondo, Shoichi Hazama, Toru Kawaoka et al. · PubMed · 2008 · 113 citations

Medicine, Immunology, Oncology +17

Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial

Akira Tsuburaya, Kazuhiro Yoshida, Michiya Kobayashi et al. · The Lancet Oncology · 2014 · 110 citations

Medicine, Oncology, Pharmacology +11

A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome

Shoichi Hazama, Yusuke Nakamura, Hiroko Takenouchi et al. · Journal of Translational Medicine · 2014 · 93 citations · Full text

Medicine, Immunology, Oncology +17

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Shoichi Hazama, Yusuke Nakamura, Hiroaki Tanaka et al. · Journal of Translational Medicine · 2014 · 87 citations · Full text

Medicine, Immunology, Pharmacology +17